Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 May 5.

Published in final edited form as: Mod Pathol. 2020 Dec 10;34(5):862–874. doi: 10.1038/s41379-020-00724-3

Table 2.

Subtype predictions across TCGA subtype labels, by BRAF/RAS mutation status.

	Molecular alteration	Predictions
		PTC-classic	PTC-EFG	NIFTP
PTC-FV	RAS mutant	0 (0%)	3 (10%)	27 (90%)
	BRAF mutant	8 (42%)	6 (32%)	5 (26%)
	RAS/BRAF non-mutant	3 (6%)	8 (16%)	39 (78%)
PTC-NOS	RAS mutant	2 (10%)	2 (10%)	16 (80%)
	BRAF mutant	145 (63%)	33 (14%)	54 (23%)
	RAS/BRAF non-mutant	24 (30%)	25 (31%)	31 (39%)
PTC-tall	RAS mutant	0 (0%)	0 (0%)	0 (0%)
	BRAF mutant	30 (94%)	2 (6%)	0 (0%)
	RAS/BRAF non-mutant	4 (100%)	0 (0%)	0 (0%)
PTC-FV	BRAF-like	9 (47%)	8 (42%)	2 (11%)
PTC-FV	RAS-like	1 (1%)	6 (9%)	61 (90%)
PTC-NOS	BRAF-like	125 (57%)	41 (19%)	55 (25%)
PTC-NOS	RAS-like	6 (13%)	7 (15%)	35 (73%)
PTC-tall	BRAF-like	27 (93%)	2 (7%)	0 (0%)
PTC-tall	RAS-like	1 (100%)	0 (0%)	0 (0%)

Table excludes a single dual RAS/BRAF mutant PTC-NOS.